Answers are grounded in this paper and cite their sources.
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with an 8% five-year survival rate. KRAS, the major oncogenic driver, triggers several phosphorylation cascades, making phosphatases, particularly protein phosphatase 2A (PP2A), which accounts for 50–70% of cellular phosphatase activity, a critical regulator. Through association with multiple regulatory subunits, PP2A modulates both tumor-suppressive and tumor-promoting functions. The tumor-suppressive function is often inhibited in PDAC by endogenous inhibitors like SET and CIP2A, which are frequently upregulated. This review examines the multifaceted roles of PP2A in PDAC, with a focus on its published roles in KRAS-MYC signaling, DNA damage response, and epithelial-to-mesenchymal transition, as well as current and emerging therapeutic strategies aimed at modulating PP2A activity.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: